Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.
Actively Recruiting
Researchers are investigating how intravitreal faricimab injections and fluocinolone acetonide intravitreal implants compare with observation in preventing long-term vision loss caused by radiation retinopathy after treatment of choroidal melanoma using iodine-125 plaque brachytherapy. This Phase 3 randomized trial aims to assess whether repeated treatments can improve visual acuity outcomes and alter the progression of macular edema resulting from radiation damage to the retina. Participants will be randomly assigned to one of three groups repeated faricimab injections, fluocinolone acetonide intravitreal implants, or observation with treatment only if macular edema develops. Faricimab is given as a 6.0 mg intravitreal injection at the start and every 3 months thereafter. The fluocinolone acetonide implant 0.19 mg is placed at the beginning and again at 24 months. The observation group receives no initial treatment but is monitored closely. During the study, participants will undergo vision tests to measure changes in visual acuity over 3 years. Imaging techniques including widefield color photos, fluorescein angiography, and OCT angiography will track retinal changes and macular edema development. Researchers will monitor safety, visual outcomes, and the natural course of radiation retinopathy. The total study duration extends up to the primary completion date, nearly six years after the start, allowing for long-term evaluation.
Actively Recruiting
Researchers are studying diabetic retinal disease to better understand the structural and functional changes in the retina of people with diabetes. The goal is to improve the development of new therapies by identifying more effective primary and surrogate endpoints for regulatory trials. Current endpoints require long study durations and many participants, so this research aims to find better ways to measure disease progression. Participants include people with diabetes at various stages of diabetic retinopathy as well as age-matched non-diabetic controls. The study observes retinal function through various diagnostic tests such as visual acuity, reading speed, visual field testing, contrast sensitivity, electroretinography, and several imaging techniques like ultrawide field color photography, fluorescein angiography, optical coherence tomography, and optical coherence tomography angiography. Participants are grouped based on their diabetic retinopathy severity scale without center-involved diabetic macular edema. During the study, participants undergo regular assessments using these diagnostic tests to monitor retinal function and disease progression over several years. The primary outcomes focus on whether these tests performance worsens as diabetic retinopathy severity increases. The study involves informed consent and includes people aged 18 and older. The observation period extends up to six years, with primary outcome measures evaluated at four years. Safety and disease progression are closely monitored throughout the study.
Actively Recruiting
Researchers are studying diabetic retinal disease, focusing on eyes treated for diabetic macular edema DME with anti-VEGF agents. The study aims to better understand retinal structural and functional changes in people with diabetes to develop and validate new clinical and surrogate endpoints. This is important because current endpoints require long trials and many participants to show treatment effects. Participants will receive injections of anti-vascular endothelial growth factor anti-VEGF at baseline, 4, and 8 weeks. Afterward, they will be monitored every 8 weeks, and injections will continue only if the eye shows center-involved DME or visual acuity worse than 2020 due to DME. Participants may be assessed more frequently if symptoms occur. The study includes three groups based on severity of center-involved DME. During the study, participants will undergo various assessments including multifocal pupillographic objective perimetry, contrast sensitivity, electroretinography, reading performance, visual field function, diabetic retinopathy severity, retinal vascular pathology, retinal structure, and microvascular parameters. These measures will be tracked from baseline up to one year to evaluate changes. The study runs from July 2026 to December 2027 and involves adult participants with diabetic retinal disease.
Actively Recruiting
The trial investigates pediatric patients aged 18 to 21 years diagnosed with moderate to severe obstructive sleep apnea OSA. It evaluates the use of the Inspire Upper Airway Stimulation UAS System implant as a treatment option. This prospective, multi-center, single-arm registry study aims to collect data on safety and effectiveness after the device implantation, following participants for up to 5 years post-implant. Participants will receive the Inspire UAS System implant targeted at managing OSA symptoms. The study includes one group of pediatric subjects meeting the approved device indication and eligibility criteria. Data collection occurs at baseline before implantation, at implant activation one month post-implant, then at 6 months, and annually up to 5 years after implant. During the study, participants will attend scheduled visits for sleep studies, questionnaires, and device assessments to monitor safety and treatment effects. Researchers will evaluate device-related adverse events, changes in apnea hypopnea index AHI, oxygen desaturation index ODI, total sleep time with low oxygen saturation T90, and daytime sleepiness using the Epworth Sleepiness Scale ESS. Ongoing follow-up ensures comprehensive safety and effectiveness data over the full 5-year period.
Actively Recruiting
This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.
Actively Recruiting
Researchers are studying the best timing for vitrectomy surgery to remove symptomatic epiretinal membranes ERM, a condition affecting the retina that can cause visual distortion and loss. The trial compares immediate surgery to deferred surgery, which is usually recommended when vision worsens to 2040 or worse. The study aims to understand how delaying surgery impacts visual outcomes, identify factors predicting surgery success or disease progression, and evaluate new measures of visual distortion and reading speed in this condition. Participants are randomly assigned to one of two groups immediate vitrectomy surgery within one month of randomization, or deferred vitrectomy where surgery is performed only if vision declines significantly, symptoms worsen, or complications arise. The deferred group is closely monitored to detect changes that would trigger surgery. This approach helps researchers compare outcomes between early and delayed surgical intervention for ERM. During the study, participants undergo regular vision assessments, including evaluating visual acuity changes over 36 months, which is the primary outcome measure. Researchers also collect data on visual distortion and reading speed to better understand symptoms. Safety and progression are closely monitored, and surgery timing decisions are guided by defined criteria or participant preference. The total study duration extends up to three years, providing long-term insight into ERM management.
Actively Recruiting
Researchers are evaluating the safety and pain relief effects of the ReneuRx device compared to corticosteroid injections in adults aged 22 to 80 who suffer from moderate to severe chronic lateral hip pain associated with Greater Trochanteric Pain Syndrome. This trial aims to understand how the nerve selective therapy device performs against standard treatment in easing hip pain. The study is randomized and controlled, focusing on treatment outcomes and safety over time. Participants will be randomly assigned to receive either the ReneuRx device injection around the femoral nerve branches or a single corticosteroid injection consisting of 40mg Triamcinolone acetate mixed with saline. The treatment is administered once, and participants will be followed closely during the study period. The trial compares these two interventions in parallel groups to assess their analgesic performance and monitor any side effects. During the study, participants will attend scheduled visits and complete quality of life and pain questionnaires over a follow-up period of about 6 to 12 months. Researchers will measure primary effectiveness at 3 months post-treatment and continue to monitor safety for an average of 12 months. Various secondary effectiveness assessments will be conducted at multiple time points up to 12 months. This comprehensive monitoring includes patient-reported outcomes to understand improvements and any adverse events throughout the study.